The Drug Check eTEN Project to validate an on-line pan-European service

The objective of the Drug Check project is to validate an on-line, pan-European service, which gathers, organises, stores, makes available and presents information and data covering pharmaceuticals and their interactions. The service provides a user-friendly, reliable, intelligent and fast mechanism to accept questions and advanced queries, process them and offer accurate answers justified with the relevant bibliography, in order to assist healthcare professionals in making the proper decisions on medication prescriptions and pharmaceutical treatments both in and out of the hospital without interrupting healthcare delivery.

The service will be offered as a web-based/mobile application to healthcare professionals and institutions (e.g. hospitals, research organisations) following the ASP (application service provider) model, and its functionality will facilitate users to gain optimum access to the service at any time, from any place using various devices (computer, mobile phones, etc), at low cost and with enhanced userfriendliness and usability, in order to become a fast, reliable, accurate and effective companion to their everyday practise. A consortium of academic experts, IT integrators and Consulting companies will offer the service via Internet and mobile platforms to healthcare professionals.

It is envisaged that the service, after its deployment, will be an invaluable companion to a wide range of healthcare professionals, by enhancing their skills and empowering their decision-making processes, thus reducing unwanted effects and improving cost-effectiveness of patients' treatment and therefore contributing to better healthcare services for all citizens.

The DrugCheck service can be a valuable tool to all healthcare professionals who want fast access to trusted and verified information (through latest bibliography and publications) about potential interactions between pharmaceuticals. The service is not limited to the information offered from the drug's documentation provided from the company but offers information on mechanisms and results of interactions between pharmaceuticals.

DrugCheck service offers the following functionality:

  • Drug Interactions: The service describes the various types of interactions between pharmaceuticals (and also nutritional elements).
  • Detailed description of the interaction mechanism and the mechanism in case of special patients groups, location of interaction, pharmacokinetic properties etc.
  • Reference to the necessity of the measurement of the levels of some of the medicines already administered or scheduled to be administered to the patient, in order to decide the right dose of the medicine to minimise the risk of potential interactions
  • Effect of interaction and management of effects
  • References to source of knowledge (bibliography) and links to documentation.

For further information, please visit:
http://www.drug-check.org

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...